Home › Cases › SVT in Pregnancy
SVT
SVT in Pregnancy
6 questions
Question 1 · SVT in pregnancy
Correct answer: Drug safety in pregnancy must be considered. Fetal monitoring needed. Cardioversion is safe in all trimesters if needed
Why
SVT in pregnancy: more common (hormonal changes, increased volume). Fetal monitoring essential during treatment. Adenosine: safe in pregnancy (short-acting, does not cross placenta significantly) — first-line after failed vagal manoeuvres. DC cardioversion: safe in all trimesters (fetal heart not in current path). Fetal monitoring during treatment.
Key point
SVT in pregnancy: adenosine safe first-line. DC cardioversion safe in all trimesters. Fetal monitoring throughout.
Question 2 · Medication safety
Correct answer: IV adenosine 6mg — crosses placenta minimally, short-acting, no teratogenicity, safe in all trimesters
Why
Adenosine in pregnancy: drug of choice for SVT after failed vagal manoeuvres. Minimal placental transfer, extremely short half-life (10 seconds), no reported teratogenicity. Transient fetal bradycardia possible but brief. Verapamil: second choice but can cause maternal hypotension. Amiodarone: AVOID in pregnancy (fetal thyroid toxicity, growth restriction).
Key point
Pregnancy SVT: adenosine is first-line drug. Amiodarone CONTRAINDICATED (fetal thyroid toxicity). Verapamil second.
Question 3 · DC cardioversion in pregnancy
Correct answer: Yes — DC cardioversion is safe in all trimesters. Fetal monitoring before and after. Obstetric and anaesthetic team present
Why
DC cardioversion in pregnancy: safe in all trimesters. The fetal heart is not in the current path. Perform with obstetric and anaesthetic team present. Fetal monitoring before and after. Standard energy levels used. Rare fetal VF reported theoretically but not in practice.
Key point
DC cardioversion: safe in all trimesters of pregnancy. Obstetric + anaesthetic team present. Fetal monitor before and after.
Question 4 · Fetal effects of tachycardia
Correct answer: Maternal hypotension from tachycardia reduces placental perfusion → fetal distress. Prolonged maternal tachycardia also reduces fetal oxygenation
Why
Maternal SVT and fetus: maternal tachycardia → reduced diastolic filling → reduced cardiac output → reduced uteroplacental blood flow. Prolonged → fetal distress. Fetal bradycardia/decelerations on CTG. Expedite treatment. If >34 weeks and failing treatment: early delivery may be needed.
Key point
Maternal SVT → reduced placental perfusion → fetal distress. Urgent treatment. CTG monitoring. May need early delivery if >34w.
Question 5 · Long-term management in pregnancy
Correct answer: Metoprolol or verapamil for prophylaxis — relatively safe in 2nd and 3rd trimester. Ablation can be performed post-partum or with lead shielding
Why
Recurrent SVT in pregnancy prophylaxis: metoprolol (preferred — most data), verapamil. Both relatively safe but avoid in first trimester. Flecainide: limited data, caution. Ablation: can be deferred to post-partum; if absolutely necessary during pregnancy — perform with radiation shielding at >20 weeks.
Key point
SVT prophylaxis in pregnancy: metoprolol or verapamil (avoid 1st trimester). Ablation post-partum preferred.
Question 6 · Post-partum arrhythmia
Correct answer: Post-partum, once clinically stable and bleeding settled. Breastfeeding: most antiarrhythmics relatively safe but discuss
Why
Post-partum SVT: ablation can be performed soon after delivery once stable. Most antiarrhythmics excreted in breast milk at very low levels — metoprolol, verapamil considered acceptable for breastfeeding. Adenosine for acute episodes: safe. Flecainide: avoid while breastfeeding. Breastfeeding not a contraindication to ablation.
Key point
Post-partum: ablation when clinically stable. Metoprolol and verapamil acceptable while breastfeeding. Not a contraindication.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.